FDA Advisory Panel Endorses Grail's DNA-Based Cancer Blood Test Amidst Efficacy Concerns
A federal advisory panel to the Food and Drug Administration (FDA) has endorsed Grail Inc.'s Galleri test, a DNA-based blood test designed to detect signs of various cancers in seemingly healthy individuals. The panel voted 7-2, with one abstention, concluding that the test offers more potential benefits than risks, despite significant questions regarding its efficacy. The Galleri test does not diagnose cancer directly but identifies signals that may indicate the presence of over 50 types of cancer, including those for which no routine screenings currently exist, such as liver and ovarian cancer. Individuals receiving a positive result would require further medical evaluation. This endorsement marks the first time a federal advisory group has supported such an experimental approach to multi-cancer detection. The FDA is expected to make a final decision on the test in the coming months, which could significantly broaden its availability in the U.S.
